» Articles » PMID: 9445300

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

Overview
Specialty Critical Care
Date 1998 Jan 28
PMID 9445300
Citations 257
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic pulmonary fibrosis (IPF) is a generally fatal disorder with a reported median survival of 3 to 6 yr. This has been based on relatively few studies with diagnoses inconsistently confirmed by adequate lung biopsy. Retrospective analysis of 104 patients with IPF who had open lung biopsy (OLB) at Mayo Medical Center from 1976 to 1985 was performed to establish the overall survival rate, the spectrum of histopathological subgroups and their associated prognostic significance. The study group consisted of 54 men and 50 women with a median age of 63 yr. Median survival was 3.8 yr after diagnosis by OLB with an estimated 10 yr survival of 27%. Current histopathologic review showed a heterogeneous group including usual interstitial pneumonia (UIP), desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia/fibrosis (NSIP), acute interstitial pneumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), and others. Median survival of the UIP group was 2.8 yr which is significantly worse (p < 0.001) than for other subgroups of chronic interstitial pneumonias. IPF includes several histopathologic subgroups with significantly different survival rates. Patients with UIP have worse survival than patients with other types of idiopathic chronic interstitial pneumonias including NSIP. Accurate histopathologic classification is essential for prognostication in patients with IPF.

Citing Articles

Classification of Patients Based on Dyspnea and Desaturation During Exercise in Interstitial Lung Disease.

Otake K, Misu S, Yamamoto A, Yamaguchi T, Nagatani C, Sakai H Respir Care. 2025; 70(1):56-64.

PMID: 39964866 PMC: 11824878. DOI: 10.1089/respcare.11712.


Novel kinase 1 regulates CD8+T cells as a potential therapeutic mechanism for idiopathic pulmonary fibrosis.

Tan Z, Lou Y, Qin Y, Lin W, Liang B, Sooranna S Int J Med Sci. 2024; 21(6):1079-1090.

PMID: 38774751 PMC: 11103402. DOI: 10.7150/ijms.93510.


Effects of Natural Products through Inhibiting Endoplasmic Reticulum Stress on Attenuation of Idiopathic Pulmonary Fibrosis.

Deng J, Liu J, Chen W, Liang Q, He Y, Sun G Drug Des Devel Ther. 2024; 18:1627-1650.

PMID: 38774483 PMC: 11108075. DOI: 10.2147/DDDT.S388920.


Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.

Singh S, Wairkar S AAPS PharmSciTech. 2024; 25(4):78.

PMID: 38589751 DOI: 10.1208/s12249-024-02793-y.


Dysregulated bidirectional epithelial-mesenchymal crosstalk: a core determinant of lung fibrosis progression.

Yao L, Xu Z, Davies D, Jones M, Wang Y Chin Med J Pulm Crit Care Med. 2024; 2(1):27-33.

PMID: 38558961 PMC: 7615773. DOI: 10.1016/j.pccm.2024.02.001.